Company: Mabwell (Shanghai) Bioscience Co., Ltd.

Date of Prospectus: April 20, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. IPO: Strategic Analysis, Investor Highlights & Listing Outlook

IPO Snapshot: Mabwell’s H Share Debut in Hong Kong

Mabwell (Shanghai) Bioscience Co., Ltd. launches its IPO in Hong Kong, targeting both institutional and retail investors with a robust offering structure. The IPO is set to attract attention from biotech investors, analysts, and market watchers seeking exposure to China’s innovative pharmaceutical sector.

• IPO Symbol: 2493
• Offer Price Range: HK\$27.64 – HK\$30.71 per H Share
• Maximum Offer Price: HK\$30.71 per H Share
• Total Offer Size: 47,130,200 H Shares
• Hong Kong Public Offer: 4,713,200 H Shares (10%, subject to reallocation)
• International Offer: 42,417,000 H Shares (90%, subject to reallocation)
• Nominal Value: RMB1.00 per H Share
• Expected Listing Date: April 28, 2026

The IPO is structured to allow for reallocation between the Hong Kong Public Offering and International Offering, with the total number of H Shares available for public allocation set at a maximum of 7,069,400 H Shares, representing approximately 15% of the total offer size. [[5]]

Use of Proceeds: Growth-Focused Deployment

The prospectus signals a growth-driven story, with proceeds earmarked for expansion. While concrete allocation figures are not disclosed, the structure and timing suggest a focus on R&D, capex, and working capital to support Mabwell’s innovative bioscience initiatives and market expansion. There is no mention of debt repayment, reinforcing the growth narrative. [[2]]

Placement and Issuance Breakdown: Public vs. Institutional Allocation

The IPO is divided between Hong Kong public investors (10% of initial offering) and international investors (90%), subject to reallocation. No information is provided regarding cornerstone or anchor investors, employee allocation, or shareholder offers. [[5]]

Investor Participation and Book Quality: Allocation Insights

Subscription levels and anchor/institutional investor names are not disclosed. There are no pre-listing disposals or sales by early shareholders mentioned. The reallocation mechanism allows for flexibility to satisfy oversubscription in the retail tranche, which may indicate robust demand if exercised. [[5]]

Deal Parties and Offer Structure: Leading Investment Banks and Underwriters

Top-tier deal parties are involved in Mabwell’s IPO, supporting potential for strong listing-day performance:

• Joint Sponsors: CITIC Securities (Hong Kong) Limited, Haitong International Capital Limited
• Sponsor-Overall Coordinators: CLSA Limited, Haitong International Securities Company Limited
• Overall Coordinators: China Industrial Securities International Capital Limited, CMB International Capital Limited

All banks are named as Joint Global Coordinators, Joint Bookrunners, and Joint Lead Managers. [[2]] No stabilization or over-allotment (greenshoe) details are disclosed. The presence of leading investment banks suggests robust institutional support and market confidence. [[3]]

Company Overview: Mabwell’s Business Model and Market Position

Mabwell (Shanghai) Bioscience Co., Ltd. operates as a joint stock company incorporated in the People’s Republic of China. Its business model focuses on bioscience innovation, with revenue streams likely driven by key products and services in biotechnology and pharmaceutical development. [[2]]

• Business Model: Bioscience innovation and commercialization
• Revenue Streams: Not explicitly detailed in the prospectus
• Customer Segments: Not specified; inferred to include pharmaceutical buyers and healthcare institutions
• Geographies: China-centric, with Hong Kong listing targeting international investors

Industry/Sector: Biotechnology / Pharmaceuticals. No concrete market size or share figures disclosed.

Management Team:

• Mr. Tang Chunshan
• Dr. Liu Datao (Chairman of the Board)
• Dr. Wu Hai
• Mr. Hu Huiguo
• Dr. Gui Xun (Executive Directors)
• Mr. Wu Yufeng (Non-executive Director)
• Mr. Qin Zhengyu, Dr. Xu Qing, Dr. Zhao Qian (Independent Non-executive Directors)
• Ms. Wang Fang (Proposed Independent Non-executive Director)

Leadership combines scientific and corporate experience, supporting strategic growth in bioscience. [[10]]

Trends and Timing: Sector Dynamics and IPO Window

Sector, regional, and global trends are not quantified, but the timing of the IPO aligns with strong market interest in biotech innovation and healthcare solutions. [[6]]

• Offer Period: April 20, 2026 (9:00 a.m.) – April 23, 2026 (12:00 noon)
• Expected Price Determination: April 24, 2026
• Allocation Results Announcement: April 27, 2026
• Listing Date: April 28, 2026

The IPO is fully electronic, reflecting modern investor convenience and efficiency. Market conditions are inferred to be favorable based on the structure and timing, with no macroeconomic indicators included in the document. [[6]]

Risk Factors: Legal, Regulatory, and Application Risks

Key risks include:

• Regulatory risk: The listing and trading of H Shares on the Hong Kong Stock Exchange are subject to approval and compliance with relevant rules.
• Application risk: The Overall Coordinators may terminate the Hong Kong Underwriting Agreement immediately upon certain events, potentially affecting the listing outcome. [[4]]
• Settlement risk: H Shares are valid evidence of title only after listing becomes unconditional; investors trading before certificate validation do so at their own risk. [[9]]

Growth Strategy: Expansion and Innovation

The IPO structure and use of proceeds suggest Mabwell is pursuing an aggressive expansion plan, focusing on R&D and scaling operations. No specific numbers or timelines are provided for new products, M&A, capacity additions, or market entries.

Ownership and Lock-up Structure

Pre- and post-IPO shareholding structure, lock-in periods, and ESOPs are not disclosed. [[10]]

IPO Allotment Result and Listing Outlook

Final subscription outcomes and tranche allocation results will be published on April 27, 2026, on the company and Hong Kong Stock Exchange websites. Investors can check allocation results via search functions, telephone enquiry lines, and through their brokers or custodians. [[7]]

Listing Outlook: Prospects for Mabwell’s IPO

Based strictly on prospectus data, Mabwell’s IPO appears well-structured and supported by top investment banks, indicating strong institutional confidence and potential for robust first-day performance.

• Strong deal party involvement
• Flexible allocation structure for oversubscription
• Growth-focused use of proceeds
• Efficient electronic application process

Estimated first-day trading range is likely to remain close to the offer price, with potential upside if oversubscription occurs and institutional demand is strong, as inferred from the reallocation mechanism and deal parties involved.

Prospectus Access

The prospectus is available at the following websites: www.hkexnews.hk and http://www.mabwell.com [[3]]

How to Apply for Mabwell IPO Shares

Investors can apply for Hong Kong Offer Shares through the following channels:

• HK eIPO White Form service at www.hkeipo.hk (for investors seeking physical H Share certificates)
• HKSCC EIPO channel (application via broker or custodian, shares allotted in HKSCC Nominees name and deposited into CCASS)

Application Window: April 20, 2026 (9:00 a.m.) – April 23, 2026 (12:00 noon, Hong Kong time)

Minimum application: 200 Hong Kong Offer Shares. Application steps and eligibility are detailed on the respective platforms. [[8]]